Mark Holterman, MD, practices medicine at the University of Illinois College of Medicine at Peoria. As attending pediatric surgeon, he seeks out strategies for employing ethically sourced fetal stem cells in treatments of serious diseases. Dr. Mark Holterman is also active as a board member of TargaCell, Inc., a Chicago-headquartered biotech startup that has created an organ-specific system for the delivery of adult stem cells.
The company’s outpatient system is described as noninvasive and representing a major improvement over the current state-of-the-art technology, which involves catheter-based delivery. Decreasing loss and damage to stem cells, the TargaCell system effectively targets the intended organ. This results in a significant increase in stem cell retention and in turn improves organ repair activities that offer sustained pathways to recovery.
Among the areas in which the technology offers major advantages are limiting the costs related to prevention, recovery, and treatment for patients with cardiovascular disease.